Abstract
Background: The cause of cervical cancer can be traced to Human Papilloma Virus (HPV) along with other, nonviral factors. The uterine cervix is reactive to hormones, and female hormones have been implicated in cervical cancer pathogenesis. Previous studies have indicated that malignant cervical cells tend to lose Estrogen Receptor alpha (ER-α) expression in the cervical epithelium while maintaining ER-α expression in the stromal cells.
Method: We searched the Web of Science, Embase, PubMed, and Wiley Online Library databases to identify potentially relevant articles up to July 4, 2018. Keywords include uterine cervical neoplasms; receptors, estrogen; estrogen receptor alpha; estrogen receptor modulators; estrogens; cervical cancer and estrogen receptor.
Result: Discussions on molecular transitions and drug therapies offer insights into cervical cancer and the functions of estrogen receptors. We focus on molecular transitions and drug therapies for cervical cancer and ER-α targets. Finally, the targeting of downstream gene products and/or receptors to aid in cervical cancer prevention and therapy is discussed.
Conclusion: Downregulating ER-α expression may be a potential treatment regimen for cervical cancer patients and will be of great significance for patients with cervical cancer who are receiving conventional treatment for nonsurgical treatments.
Keywords: Cervical cancer, estrogen receptor alpha, drug therapy, molecular transitions, Malignant cervical cells, stromal cells.
Anti-Cancer Agents in Medicinal Chemistry
Title:Protective Effects of Downregulating Estrogen Receptor Alpha Expression in Cervical Cancer
Volume: 18 Issue: 14
Author(s): Ping Yu, Yuping Wang, Chuanxun Li, Li Lv*Jihong Wang*
Affiliation:
- Department of Pharmacology, Dalian Medical University, Dalian, Liaoning Province, 116044,China
- School of Life Sciences, Liaoning Normal University, Dalian, Liaoning Province 116029,China
Keywords: Cervical cancer, estrogen receptor alpha, drug therapy, molecular transitions, Malignant cervical cells, stromal cells.
Abstract: Background: The cause of cervical cancer can be traced to Human Papilloma Virus (HPV) along with other, nonviral factors. The uterine cervix is reactive to hormones, and female hormones have been implicated in cervical cancer pathogenesis. Previous studies have indicated that malignant cervical cells tend to lose Estrogen Receptor alpha (ER-α) expression in the cervical epithelium while maintaining ER-α expression in the stromal cells.
Method: We searched the Web of Science, Embase, PubMed, and Wiley Online Library databases to identify potentially relevant articles up to July 4, 2018. Keywords include uterine cervical neoplasms; receptors, estrogen; estrogen receptor alpha; estrogen receptor modulators; estrogens; cervical cancer and estrogen receptor.
Result: Discussions on molecular transitions and drug therapies offer insights into cervical cancer and the functions of estrogen receptors. We focus on molecular transitions and drug therapies for cervical cancer and ER-α targets. Finally, the targeting of downstream gene products and/or receptors to aid in cervical cancer prevention and therapy is discussed.
Conclusion: Downregulating ER-α expression may be a potential treatment regimen for cervical cancer patients and will be of great significance for patients with cervical cancer who are receiving conventional treatment for nonsurgical treatments.
Export Options
About this article
Cite this article as:
Yu Ping , Wang Yuping , Li Chuanxun , Lv Li*, Wang Jihong *, Protective Effects of Downregulating Estrogen Receptor Alpha Expression in Cervical Cancer, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (14) . https://dx.doi.org/10.2174/1871520618666180830162517
DOI https://dx.doi.org/10.2174/1871520618666180830162517 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nuclear Magnetic Resonance Spectroscopy of Lipids in Cancer
Current Organic Chemistry Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Antidotal Effects of Curcumin Against Agents-Induced Cardiovascular Toxicity
Cardiovascular & Hematological Disorders-Drug Targets Pharmacological Modulation of p53 Function in Cancer Therapy
Current Signal Transduction Therapy miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Molecular Testing and Personalized Treatment of Lung Cancer
Current Molecular Pharmacology Perspectives On Membrane-associated Progesterone Receptors As Prospective Therapeutic Targets
Current Drug Targets Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
Current Pharmaceutical Design The Molecular Basis of Notch Signaling Regulation: A Complex Simplicity
Current Molecular Medicine Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Challenges and Opportunities for Cancer Vaccines in the Current NSCLC Clinical Scenario
Current Topics in Medicinal Chemistry Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Nanoparticles in Gastric Cancer Management
Current Pharmaceutical Design Three-Dimensional Ultrasound in Gynecology: Current Status and Future Perspectives
Current Women`s Health Reviews Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs
Current Drug Metabolism Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Targeted Gene Therapy for Ovarian Cancer
Current Gene Therapy HPV mRNA Testing in Triage of Women with ASC-US Cytology May Reduce the Time for CIN2+ Diagnosis Compared with Repeat Cytology
Current Pharmaceutical Design Fluorine-18 Labeled Amino Acids for Oncologic Imaging with Positron Emission Tomography
Current Topics in Medicinal Chemistry